Noninvasive exams can help head off liver disease
A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH). The main risk factors for fatty liver disease include a sedentary
